オプションチェーンは、Beyond Airの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Beyond Airの市場センチメントを評価します。.

Beyond Air (NASDAQ:XAIR) 株価情報, オプションチェーン

Beyond Air

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Beyond Air Inc

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States
Study shows &gt;95% success rate, validating BE-Smart for use with esophageal brush cytology.
ProPhase Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study evaluating the performance of the BE-Smart&#x2122; molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart&#x2122; achieved greater than a 95% technical success rate, confirming the BE-Smart's ability to reliably and accurately detect our panel of biomarkers, designed to assess progression risk in Barrett's esophagus and other distal esophageal conditions. Prophase will now move to accelerated commercialization of BE-Smart&#x2122; with expected clinical launch in the next 2-3 quarters.
BE-Smart uses a proprietary panel of biomarkers and a multi-modal analysis method which together significantly increase detection of deadly cancer cells in one of the fastest growing cancer indications, esophageal denocarcinoma cancer or "EAC". EAC has a 5-year mortality rate of over 79% and surged in annual incidence over 750% since the 1970s. BE-Smart represents a technical advance in detection and prognosis which has the potential to change cost and outcomes for the large population affected by GERD, Barrett's and EAC globally.

News

PRPH

ProPhase Labs Validates BE-Smart Test; Study Demonstrates High Accuracy; Clinical Rollout Expected Within 2-3 Quarters

<a href="https://pr.report/bkw9">SideChannel, Inc.</a> (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/SDCH#OTCQB">SDCH</a>) ("SideChannel"), a leader in modern cybersecurity technology and services solutions, today announced the deployment of its Enclave zero trust software by a second service branch of the United States Department of Defense ("DoD"). The engagement, facilitated through one of SideChannel's federal resale partners, represents a key validation of Enclave's ability to meet the large scale and strict cybersecurity needs of national security environments.
The deployment includes over 5,000 Enclave agents operating on-premise within national intelligence networks. The primary use cases are asset intelligence and certificate management - two critical areas for maintaining integrity and security control in sensitive infrastructure.

SDCH

SideChannel's Cybersecurity Tool Deployed by Second US Military Branch to Boost National Defense

A2Z Cust2Mate Secures $25M Order For 3,000 Smart Carts From Trixo For Major Latin American Retail Rollout Starting 2026

RDZN

Roadzen Inks Pact With Global Energy Giant SHV Energy's Indian Subsidiary, SUPERGAS, To Deploy AI-Powered ADAS Across Its LPG Fleet

John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) is looking for FY2026 Adj EPS of $3.90-$4.35 vs $3.80 analyst estimate..

Guidance

John Wiley & Sons Sees FY2026 Adj EPS $3.90-$4.35 vs $3.80 Est

Citigroup analyst Geoff Meacham initiates coverage on Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Sell rating and announces Price Target of $6.

Price Target

Initiation

Analyst Ratings

NVAX

Citigroup Initiates Coverage On Novavax with Sell Rating, Announces Price Target of $6

SYRE

Spyre Therapeutics Announces Interim Phase 1 Results For Two Next-Generation TL1A Antibody Programs, And Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

<ul>
<li>Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients are most likely to benefit from BOT/BAL treatment</li>
<li>Collaboration builds on landmark 2024 Cancer Discovery study elucidating botensilimab's unique FcγR-mediated immune activation underlying activity in refractory tumors</li>
<li>Supports AI-enabled biomarker discovery, aligning with the national priorities and the FDA to expand access to personalized cancer treatment</li>
</ul>
Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1). The collaboration harnesses Noetik's proprietary virtual cell foundation models and large-scale, multimodal tumor data to uncover novel insights into the biology of tumor immunology. Together, the teams will deploy Noetik's first-in-class foundation models directly on clinical results with the aim to enrich clinical efficacy.

AGEN

Agenus Announces Research Collaboration To Develop Predictive Biomarkers Of Response To Clinical Stage IO Combination, Botensilimab

AerCap And AFI KLM E&M To Form LEAP Engine Leasing JV To Support Global A320neo And 737 MAX Operations

John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $1.27 by 7.87 percent. This is a 13.22 percent increase over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $442.58 million which beat the analyst consensus estimate of $434.90 million by 1.77 percent. This is a 5.52 percent decrease over sales of $468.46 million the same period last year.

Earnings

Earnings Beats

John Wiley & Sons Q4 Adj. EPS $1.37 Beats $1.27 Estimate, Sales $442.58M Beat $434.90M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) with a Buy rating and announces Price Target of $6.

GALT

HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) has edged past Elon Musk's EV giant in global sales for the first time, according to the International Council on Clean Transportation or ICCT.
What Happened: Chinese automakers are "building significant leads in the zero-emission vehicle (ZEV) market," the ICCT said in a press release as part of its third annual Global Automaker Rating on Tuesday.
BYD exceeded Tesla for the first time in 2024 in BEV (Battery Electric Vehicle) sales, the report says, while maintaining that both companies remain "leaders" in the ratings.
The report also says that the Chinese domestic market now accounts for over 11 million EVs sold annually, which is "more than half" of the total EV sales throughout the globe.
Why It Matters: The news comes in as BYD has been expanding its presence throughout multiple countries, with Europe currently <a href="https://www.benzinga.com/25/04/45097773/satellite-images-put-tesla-rival-byds-hungarian-factory-capable-of-producing-200k-units-annually-in-the-spotlight">a key area</a> for the Chinese EV giant.
The company recently launched its best-selling model in Europe, the Seagull EV, which would be called the <a href="https://www.benzinga.com/markets/25/05/45560953/byds-europe-pivot-in-full-swing-with-new-26000-affordable-ev-amid-tesla-sales-slump">Dolphin Surf EV </a>in the region for $26,000. This comes in as the automaker <a href="https://www.benzinga.com/25/04/44946809/byd-rejigs-european-strategy-amid-lack-of-market-knowledge-and-modest-dealer-network-report">overhauled its European strategy</a> after it failed to meet targets set when it entered the region.
On the other side of the coin, BYD has been <a href="https://www.benzinga.com/news/topics/25/06/45715047/byds-aggressive-pricing-triggers-ev-rat-race-stock-tumbles-authorities-voice-concern">facing criticism</a> over its aggressive discounts amid China's ongoing EV price war. The company recently released the <a href="https://www.benzinga.com/markets/tech/25/06/45855643/tesla-rival-byd-launches-15000-seal-06-sedan-as-chinas-ev-price-war-heats-up">Seal 06 EV</a> sedan in China, retailing for $15,000.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/06/45900203/xpeng-receives-10000-pre-orders-in-under-an-hour-for-new-tesla-model-3-rival-report">Xpeng Receives 10,000 Pre-Orders In Under An Hour For New Tesla Model 3 Rival: Report</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock

BYDDF

BYDDY

TSLA

Elon Musk Has A New Problem: BYD Beats Tesla In Global EV Sales Amid Europe Expansion

VTYX

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

In alignment with the Presidential Executive Order "Unleashing American Drone Dominance"
Golden, CO, June 17, 2025 (GLOBE NEWSWIRE) -- TB2 Aerospace LLC, in collaboration with Draganfly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#CSE">DPRO</a>) (FSE: 3U8A) ("Draganfly" or the "Company"), a drone solutions, and systems developer, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>), is proud to announce the successful deployment and performance of the Drone Recharging Operational Payload System (DROPS) during the U.S. Army's Sustainment Modernization Experiment 2025 (SMEX25).
Throughout SMEX25's week-long field exercises, the DROPS system, integrated with Draganfly's Commander 3XL, achieved a 100% success rate in autonomously deploying, recovering, and recharging TB2's tactical resupply pods. The event provided an opportunity to validate real-world operational performance in austere and high-demand scenarios, drawing praise from defence evaluators and technology observers alike.

CSE:DPRO

DPRO

TB2 Aerospace, In Collaboration With Draganfly, Announces Deployment Of Drone Recharging Operational Payload System During U.S. Army's SMEX25

Loop Capital analyst Alan Gould upgrades Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) from Hold to Buy and raises the price target from $80 to $100.

Upgrades

ROKU

Loop Capital Upgrades Roku to Buy, Raises Price Target to $100

PureCycle Partners With IRPC To Build 130M-Pound PP Recycling Facility In Thailand, Eyes Mid-2027 Launch

PureCycle Raises $300M To Support Global Expansion Toward 1B Pounds Capacity, Targets $600M Annual EBITDA By 2030

Needham analyst Mike Matson reiterates TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) from Hold to Hold.

Reiteration

TMDX

Needham Reiterates Hold on TransMedics Groupto Hold

Billionaire entrepreneur Mark Cuban has proposed a bold plan to revolutionize the U.S. healthcare system, eliminating traditional insurance premiums and introducing transparent pricing.
What Happened: Cuban&#8217;s recent proposal, posted on social media platform X, comes amid growing frustration with insurance clawbacks and escalating costs, spotlighted by a viral video from an American surgeon exposing insurer malpractices.
Cuban's plan allows patients to select cash-pay providers who disclose prices upfront. "I would allow patients to pick whatever cash pay provider that honors their published price," he wrote, proposing that patients pay what they can afford, with taxpayers covering the rest.
Repayments would be deducted from paychecks, capped at 10%, with unpaid debt forgiven after 15 years. "There would be zero premiums to insurance companies," he added, replacing them with a $400–500 monthly family re-insurance fee, capping annual expenses at $50,000.
The proposal also targets Pharmacy Benefit Managers (PBMs), aiming to eliminate their role in drug pricing. "No PBMs. No health care from employers," Cuban stated, drawing on his success with Cost Plus Drugs, which has slashed prescription costs by up to 80% since 2022.
Medicare and Medicaid would adopt net pricing for medications, enhancing affordability.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Still have work to do on the numbers, and this is off the top of my head. But I would allow patients to pick whatever cash pay provider that honors their published price . Have the patient commit to what they can afford to pay , (with documentation ) , and have taxpayers finance… <a href="https://t.co/NOcX55J6pJ">https://t.co/NOcX55J6pJ</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1934834421225672999?ref_src=twsrc%5Etfw">June 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/commodities/25/06/45948096/exxon-mobil-chevron-occidental-petroleum-in-focus-as-expert-says-us-economy-is-far-less-sensitive-to-an-oil-shock-amid-israel-iran-conflict" target="_blank" rel="noreferrer noopener">Exxon Mobil, Chevron, Occidental Petroleum In Focus As Expert Says ‘US Economy Is Far Less Sensitive To An Oil Shock' Amid Israel-Iran Conflict</a>
Why It Matters: Cuban has been a critic of the insurance sector for quite some time. In a recent appearance at the Stanford University Department of Medicine, he laid out exactly how he thinks insurance companies are rigging the system.
He argues that <a href="https://www.benzinga.com/news/topics/25/05/45711157/mark-cuban-says-taking-low-premium-high-deductible-plans-is-great-for-insurance-companies-you-know-who-its-not-good-for-you-guys">insurers manipulate plans annually</a>, prioritizing low premiums while subtly increasing out-of-pocket costs. This steers patients toward seemingly affordable high-deductible plans that prove disastrous during illness. 
"Depending on what's going on in the economy, those patients, particularly as they skew a little younger or a little poorer, take low-premium, <a href="https://www.benzinga.com/news/25/02/43985233/mark-cuban-calls-deductibles-the-biggest-problem-in-healthcare-system-needs-to-be-redesigned">high-deductible plans</a>," Cuban said. "Which is good for the insurance companies. You know who it's not good for? You guys." 
By "you guys," Cuban meant the doctors and hospitals who end up taking on the financial risk. If a patient can&#8217;t pay the deductible, the insurer has already gotten its money, but the provider hasn&#8217;t. "And you also take on the brand and reputational risk… Did you cause the problem? No,&#8221; Cuban added.
Price Action: Here&#8217;s how insurance companies&#8217; linked exchange-traded funds have been performing this year. These ETFs outperformed the S&amp;P 500 and the S&amp;P Insurance Select Industry indices, which have risen by 2.80% and 3.84% on a year-to-date basis, respectively. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>SPDR S&amp;P Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIE#NYSE">KIE</a>)</td>
<td>3.92%</td>
<td>17.36%</td>
</tr>
<tr>
<td>iShares US Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAK#NYSE">IAK</a>)</td>
<td>5.42%</td>
<td>17.52%</td>
</tr>
<tr>
<td>Invesco KBW Property &amp; Casualty Insurance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWP#NASDAQ">KBWP</a>)</td>
<td>6.25%</td>
<td>19.38%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Tuesday. The SPY was down 0.53% at $599.51, while the QQQ declined 0.56% to $531.30, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pr</a>o data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45967469/us-equity-funds-are-raking-in-billions-these-are-the-ones-beating-trumps-tariff-shock-in-2025">US Equity Funds Are Raking In Billions—These Are The Ones Beating Trump&#8217;s Tariff Shock in 2025</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Photo Courtesy: Kathy Hutchins On Shutterstock

Insurance

iShares Dow Jones US Insurance Index Fund

KBWP

Mark Cuban Floats Bold Healthcare Plan: 'Zero Premiums To Insurance Companies' With A Cash-Pay Revolution

JP Morgan analyst Anthony Paolone downgrades FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) from Overweight to Neutral and lowers the price target from $14 to $12.

Downgrades

JP Morgan Downgrades FrontView REIT to Neutral, Lowers Price Target to $12

Health Care

Press Releases

General

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Financing

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Management

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Legal

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections  Using gaseous Nitric Oxide (gNO)

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Comments

Beyond Air

Beyond Air (XAIR) オプション

Beyond Air (NASDAQ:XAIR) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル